Prophase Labs, INC. (PRPH) — SEC Filings

Q: What are the key financial highlights for Prophase Labs, INC.?

Key financial highlights for Prophase Labs, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Prophase Labs, INC.?

Key executives at Prophase Labs, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Prophase Labs, INC. stock?

Risk factors for Prophase Labs, INC. (PRPH) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Prophase Labs, INC.?

Forward-looking statements and predictions from Prophase Labs, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Prophase Labs, INC.. Recent 8-K filing on Dec 19, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Prophase Labs, INC. on SEC EDGAR

Overview

Prophase Labs, INC. (PRPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: ProPhase Labs, Inc. filed an 8-K on December 19, 2025, reporting an event that occurred on December 12, 2025. The filing pertains to "Other Events" and "Financial Statements and Exhibits" but does not specify the exact nature of these events or any associated financial figures within the provided te

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Prophase Labs, INC. is neutral.

Filing Type Overview

Prophase Labs, INC. (PRPH) has filed 34 8-K, 4 8-K/A, 5 10-Q, 4 DEF 14A, 1 S-1, 1 10-K/A, 1 10-K with the SEC between May 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

ProPhase Labs Files 8-K — 8-K · Dec 19, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on December 19, 2025, reporting an event that occurred on December 12, 2025. The filing pertains to "Other Events" and "Financi
ProPhase Labs Files 8-K/A Amendment — 8-K/A · Dec 18, 2025 Risk: low
ProPhase Labs, Inc. filed an amendment (8-K/A) on December 18, 2025, to its report originally dated December 10, 2025. This amendment primarily concerns changes
8-K/A Filing — 8-K/A · Dec 12, 2025
ProPhase Labs Files 8-K on Shareholder Votes & Financials — 8-K · Nov 26, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on November 26, 2025, reporting on matters submitted to a vote of security holders and financial statements. The earliest event
8-K Filing — 8-K · Nov 25, 2025
ProPhase Labs Files 8-K on Financials — 8-K · Nov 19, 2025 Risk: low
On November 19, 2025, ProPhase Labs, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
ProPhase Labs' Revenue Plummets Amid Diagnostic Business Exit — 10-Q · Nov 19, 2025 Risk: high
ProPhase Labs, Inc. (PRPH) reported a net loss of $6.839 million for the three months ended September 30, 2025, compared to a net loss of $6.587 million in the
ProPhase Labs Pivots to Crypto, Proposes Tokenized Shares — DEF 14A · Oct 31, 2025 Risk: high
ProPhase Labs, Inc. (PRPH) is seeking stockholder approval for a significant strategic pivot towards digital assets and blockchain technology at a Special Meeti
ProPhase Labs Registers 226M Shares for Resale Amidst Bankruptcy Filing — S-1 · Oct 21, 2025 Risk: high
ProPhase Labs, Inc. (PRPH) filed an S-1 on October 21, 2025, to register up to 226,310,704 shares of common stock for resale by selling stockholders. These shar
ProPhase Labs Enters Material Definitive Agreement — 8-K · Oct 15, 2025 Risk: medium
On October 9, 2025, ProPhase Labs, Inc. entered into a material definitive agreement. The company, formerly known as Quigley Corp, is incorporated in Delaware a
ProPhase Labs Enters Material Definitive Agreement — 8-K · Sep 18, 2025 Risk: medium
On September 18, 2025, ProPhase Labs, Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement, its term
ProPhase Labs Files 8-K with Key Corporate Changes — 8-K · Sep 15, 2025 Risk: medium
On September 15, 2025, ProPhase Labs, Inc. filed an 8-K report detailing several significant corporate events. These include the entry into a material definitiv
ProPhase Labs Terminates Material Agreement — 8-K · Aug 28, 2025 Risk: medium
ProPhase Labs, Inc. filed an 8-K on August 28, 2025, to report the termination of a material definitive agreement. The filing does not specify the counterparty
ProPhase Labs Files 8-K Report — 8-K · Aug 19, 2025 Risk: low
On August 19, 2025, ProPhase Labs, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regu
ProPhase Labs Files Definitive Proxy Statement — DEF 14A · Aug 15, 2025 Risk: medium
ProPhase Labs, Inc. filed its definitive proxy statement on August 15, 2025, for its annual meeting. The filing, designated as DEF 14A, outlines the company's g
ProPhase Labs Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disc
ProPhase Labs Narrows Loss to $0.51M Amid Strategic Divestiture — 10-Q · Aug 13, 2025 Risk: high
ProPhase Labs, Inc. (PRPH) reported a net loss of $0.51 million for the six months ended June 30, 2025, a significant improvement from the $12.42 million net lo
ProPhase Labs Announces Director and Officer Changes — 8-K · Aug 6, 2025 Risk: medium
ProPhase Labs, Inc. announced on August 6, 2025, changes related to its board of directors and executive officers. The filing indicates a departure of directors
ProPhase Labs Files 8-K — 8-K · Jul 29, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on July 29, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Event
ProPhase Labs Enters Material Agreement, Reports Financial Obligations — 8-K · Jul 28, 2025 Risk: medium
ProPhase Labs, Inc. announced on July 28, 2025, that it entered into a material definitive agreement. The company also reported the creation of a direct financi
ProPhase Labs Files 8-K — 8-K · Jul 25, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on July 25, 2025, reporting on matters submitted to a vote of security holders and other events. The filing does not contain sp
ProPhase Labs Files 8-K with Corporate Updates — 8-K · Jul 23, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on July 23, 2025, reporting on various events and financial statements. The filing details the company's principal executive of
ProPhase Labs Files 8-K Report — 8-K · Jul 21, 2025 Risk: low
On July 21, 2025, ProPhase Labs, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regula
ProPhase Labs Faces Delisting Concerns — 8-K · Jul 1, 2025 Risk: high
ProPhase Labs, Inc. filed an 8-K on July 1, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of
ProPhase Labs Files 8-K/A Amendment — 8-K/A · Jun 27, 2025 Risk: medium
ProPhase Labs, Inc. filed an 8-K/A on June 27, 2025, to amend a previous filing. The amendment pertains to the entry into a material definitive agreement, the c
ProPhase Labs Faces Delisting Concerns — 8-K · Jun 26, 2025 Risk: high
ProPhase Labs, Inc. filed an 8-K on June 26, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indica
ProPhase Labs Appoints New Directors, Adjusts Executive Pay — 8-K · Jun 25, 2025 Risk: medium
ProPhase Labs, Inc. announced on June 25, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new director
ProPhase Labs' Executive Equity Awards Hit Zero in 2023-2024 — DEF 14A · Jun 23, 2025 Risk: medium
ProPhase Labs, Inc. (PRPH) filed its DEF 14A on June 23, 2025, outlining executive compensation for the fiscal years ending December 31, 2023, and December 31,
ProPhase Labs Files 8-K on Financials — 8-K · May 20, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on May 20, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclos
ProPhase Labs Files Q1 2025 10-Q — 10-Q · May 20, 2025 Risk: low
ProPhase Labs, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter
ProPhase Labs Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: low
ProPhase Labs, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, previously known as Quigley Corp,
ProPhase Labs Files 2024 10-K — 10-K · Apr 1, 2025 Risk: medium
ProPhase Labs, Inc. filed its 2024 10-K report, detailing its operations and financial standing for the fiscal year ending December 31, 2024. The company, forme
ProPhase Labs Files 8-K on Financials — 8-K · Mar 31, 2025 Risk: low
ProPhase Labs, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing also includes financial statement
ProPhase Labs Appoints New Directors and CMO — 8-K · Feb 21, 2025 Risk: medium
ProPhase Labs, Inc. announced on February 17, 2025, changes in its executive and director roles. The company elected two new directors, Dr. David G. Nichols and
ProPhase Labs Announces Board and Officer Changes — 8-K · Feb 13, 2025 Risk: medium
ProPhase Labs, Inc. announced on February 7, 2025, changes related to its board of directors and officers. The filing indicates a departure of directors or cert
ProPhase Labs Enters Material Definitive Agreement — 8-K · Jan 30, 2025 Risk: medium
On January 29, 2025, ProPhase Labs, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement or any a
ProPhase Labs (PRPH) Files 8-K with Office Location — 8-K · Jan 23, 2025 Risk: low
On January 16, 2025, ProPhase Labs, Inc. (PRPH) filed an 8-K report. The filing confirms the company's principal executive offices are located at 711 Stewart Av
ProPhase Labs Faces Nasdaq Delisting Warning — 8-K · Dec 27, 2024 Risk: high
ProPhase Labs, Inc. received a notice on December 26, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The
ProPhase Labs Enters Material Definitive Agreement — 8-K · Nov 13, 2024 Risk: medium
ProPhase Labs, Inc. announced on November 7, 2024, that it entered into a material definitive agreement. The company, formerly known as Quigley Corp, is incorpo
ProPhase Labs Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
ProPhase Labs, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine mon
ProPhase Labs Files 8-K — 8-K · Nov 7, 2024 Risk: low
ProPhase Labs, Inc. filed an 8-K on November 7, 2024, to report other events and financial statements. The filing does not contain specific details about the na
ProPhase Labs Changes Auditors to EisnerAmper LLP — 8-K · Oct 18, 2024 Risk: medium
ProPhase Labs, Inc. announced on October 18, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public a
ProPhase Labs Changes Independent Auditor — 8-K · Oct 4, 2024 Risk: medium
ProPhase Labs, Inc. filed an 8-K on October 4, 2024, reporting a change in its certifying accountant as of September 30, 2024. The company previously engaged Wi
ProPhase Labs Faces Nasdaq Delisting Threat Again — 8-K · Sep 26, 2024 Risk: high
ProPhase Labs, Inc. announced on September 20, 2024, that it received a notice from Nasdaq indicating a failure to meet the minimum bid price requirement for co
ProPhase Labs Files Amendment to Material Agreement Filing — 8-K/A · Aug 22, 2024 Risk: medium
ProPhase Labs, Inc. filed an amendment (8-K/A) on August 22, 2024, to a previous filing concerning events that occurred on August 15, 2024. The amendment relate
ProPhase Labs Secures $1.5M Loan — 8-K · Aug 21, 2024 Risk: medium
On August 15, 2024, ProPhase Labs, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an undisclosed lender for $1.5 million.
ProPhase Labs Files 8-K on Financials — 8-K · Aug 14, 2024 Risk: low
ProPhase Labs, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disc
ProPhase Labs Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
ProPhase Labs, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as QUIGLEY CORP, reported its financial status. Key financia
ProPhase Labs Files 8-K on Security Holder Vote — 8-K · Jun 21, 2024 Risk: medium
On June 20, 2024, ProPhase Labs, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates a meeting
ProPhase Labs, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · May 15, 2024 Risk: low
ProPhase Labs, Inc. (PRPH) filed a Proxy Statement (DEF 14A) with the SEC on May 15, 2024. The 2024 Annual Meeting of Stockholders for ProPhase Labs, Inc. will

Risk Profile

Risk Assessment: Of PRPH's 48 recent filings, 8 were flagged as high-risk, 22 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Prophase Labs, INC.'s most recent 10-Q filing (Nov 19, 2025):

Revenue: $883,000
Net Income: ($6.839 million)
EPS: N/A
Debt-to-Equity: 8.58
Cash Position: $405,000
Operating Margin: N/A
Total Assets: $65.702 million
Total Debt: $58.841 million

Key Executives

Ted Karkus
Lance Bisesar
Dr. David G. Nichols
Mr. Robert L. Johnson
Mr. Tedd L. Weitzman
Mr. Kevin L. McGrath
Persons Employed by the Organization
Non-PEO Named Executive Officers
Mr. David M. Salkin

Industry Context

The diagnostics and genomics sectors are characterized by rapid technological advancement and evolving regulatory landscapes. ProPhase Labs is navigating this by pivoting from COVID-19 testing, which saw a boom and subsequent decline, towards genomics and novel diagnostic screening. Success hinges on innovation, market adoption of new technologies like the BE-Smart test, and managing the complexities of Laboratory Developed Tests (LDTs).

Top Tags

8-K (7) · financial-reporting (5) · pharmaceuticals (5) · material-agreement (5) · amendment (4) · corporate-governance (4) · 8-k (4) · material-definitive-agreement (4) · sec-filing (4) · Biotech (3)

Key Numbers

SEC File Number: 000-21617 — Identifies the company's filing with the SEC.
EIN: 23-2577138 — Employer Identification Number for tax purposes.
Revenues, net (Q3 2025): $883,000 — Significant decline from $1.416 million in Q3 2024
Revenues, net (YTD Q3 2025): $3.561 million — Substantial drop from $5.276 million in YTD Q3 2024
Gross profit (Q3 2025): ($123,000) — Turned negative from $215,000 profit in Q3 2024
Net loss (Q3 2025): ($6.839 million) — Increased from a net loss of $6.587 million in Q3 2024
Net loss (YTD Q3 2025): ($7.345 million) — Reduced from a net loss of $19.005 million in YTD Q3 2024, primarily due to gain from disposal of discontinued operations
Cash and cash equivalents (Sept 30, 2025): $405,000 — Decreased from $678,000 at Dec 31, 2024
Investment in unconsolidated affiliates (Sept 30, 2025): $43.657 million — New investment, indicating a strategic shift
Total current liabilities (Sept 30, 2025): $55.287 million — Increased from $32.134 million at Dec 31, 2024, largely due to accounts payable to unconsolidated affiliates and new debt instruments
Common shares outstanding (Sept 30, 2025): 41,541,205 — Increased from 29,874,029 at Dec 31, 2024, due to share issuances
Patent protection for BE-Smart: 2040 — Expected protection period for key intellectual property
Maximum equity for tokenized issuance: 4.99% — Potential dilution or new capital source
Minimum reverse/forward stock split ratio: 1-for-2 — Flexibility for Board to adjust share price
Maximum reverse/forward stock split ratio: 1-for-10 — Flexibility for Board to adjust share price

Frequently Asked Questions

What are the latest SEC filings for Prophase Labs, INC. (PRPH)?

Prophase Labs, INC. has 50 recent SEC filings from May 2024 to Dec 2025, including 34 8-K, 5 10-Q, 4 8-K/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of PRPH filings?

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Prophase Labs, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Prophase Labs, INC. (PRPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Prophase Labs, INC.?

Key financial highlights from Prophase Labs, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for PRPH?

The investment thesis for PRPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Prophase Labs, INC.?

Key executives identified across Prophase Labs, INC.'s filings include Ted Karkus, Lance Bisesar, Dr. David G. Nichols, Mr. Robert L. Johnson, Mr. Tedd L. Weitzman and 4 others.

What are the main risk factors for Prophase Labs, INC. stock?

Of PRPH's 48 assessed filings, 8 were flagged high-risk, 22 medium-risk, and 18 low-risk.

What are recent predictions and forward guidance from Prophase Labs, INC.?

Forward guidance and predictions for Prophase Labs, INC. are extracted from SEC filings as they are enriched.